Ascentage Pharma Group Net Income
| AAPG Stock | 23.82 0.62 2.67% |
As of the 14th of February 2026, Ascentage Pharma shows the risk adjusted performance of (0.09), and Mean Deviation of 2.65. Ascentage Pharma technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Ascentage Pharma information ratio, and the relationship between the coefficient of variation and value at risk to decide if Ascentage Pharma is priced correctly, providing market reflects its regular price of 23.82 per share. Given that Ascentage Pharma has information ratio of (0.14), we suggest you to validate Ascentage Pharma Group's prevailing market performance to make sure the company can sustain itself at a future point.
Ascentage Pharma Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 39.1977 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -355.7 M | -373.5 M | |
| Net Loss | -466.5 M | -489.9 M | |
| Net Loss | (1.54) | (1.62) | |
| Net Income Per E B T | 0.92 | 0.79 |
Ascentage | Net Income | Build AI portfolio with Ascentage Stock |
The Net Income trend for Ascentage Pharma Group offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Ascentage Pharma is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest Ascentage Pharma's Net Income Growth Pattern
Below is the plot of the Net Income of Ascentage Pharma Group over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Ascentage Pharma financial statement analysis. It represents the amount of money remaining after all of Ascentage Pharma Group operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Ascentage Pharma's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Ascentage Pharma's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (395.25 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Ascentage Net Income Regression Statistics
| Arithmetic Mean | (418,909,170) | |
| Coefficient Of Variation | (95.78) | |
| Mean Deviation | 312,324,606 | |
| Median | (345,307,000) | |
| Standard Deviation | 401,245,412 | |
| Sample Variance | 160997.9T | |
| Range | 1.4B | |
| R-Value | (0.54) | |
| Mean Square Error | 121678.2T | |
| R-Squared | 0.29 | |
| Significance | 0.03 | |
| Slope | (42,897,302) | |
| Total Sum of Squares | 2575966.1T |
Ascentage Net Income History
Other Fundumenentals of Ascentage Pharma
Ascentage Pharma Net Income component correlations
Ascentage Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Ascentage Pharma is extremely important. It helps to project a fair market value of Ascentage Stock properly, considering its historical fundamentals such as Net Income. Since Ascentage Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Ascentage Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Ascentage Pharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Can Biotechnology industry sustain growth momentum? Does Ascentage have expansion opportunities? Factors like these will boost the valuation of Ascentage Pharma. If investors know Ascentage will grow in the future, the company's valuation will be higher. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Ascentage Pharma demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Earnings Share (2.10) | Revenue Per Share | Quarterly Revenue Growth (0.72) | Return On Assets | Return On Equity |
The market value of Ascentage Pharma is measured differently than its book value, which is the value of Ascentage that is recorded on the company's balance sheet. Investors also form their own opinion of Ascentage Pharma's value that differs from its market value or its book value, called intrinsic value, which is Ascentage Pharma's true underlying value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Because Ascentage Pharma's market value can be influenced by many factors that don't directly affect Ascentage Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Ascentage Pharma's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Ascentage Pharma represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Ascentage Pharma's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Ascentage Pharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Ascentage Pharma's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Ascentage Pharma.
| 11/16/2025 |
| 02/14/2026 |
If you would invest 0.00 in Ascentage Pharma on November 16, 2025 and sell it all today you would earn a total of 0.00 from holding Ascentage Pharma Group or generate 0.0% return on investment in Ascentage Pharma over 90 days. Ascentage Pharma is related to or competes with Centessa Pharmaceuticals, Apogee Therapeutics, Celcuity LLC, Xenon Pharmaceuticals, CG Oncology, Zai Lab, and Legend Biotech. Ascentage Pharma is entity of United States More
Ascentage Pharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Ascentage Pharma's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Ascentage Pharma Group upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.14) | |||
| Maximum Drawdown | 16.72 | |||
| Value At Risk | (6.36) | |||
| Potential Upside | 5.25 |
Ascentage Pharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Ascentage Pharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Ascentage Pharma's standard deviation. In reality, there are many statistical measures that can use Ascentage Pharma historical prices to predict the future Ascentage Pharma's volatility.| Risk Adjusted Performance | (0.09) | |||
| Jensen Alpha | (0.43) | |||
| Total Risk Alpha | (0.67) | |||
| Treynor Ratio | (1.37) |
Ascentage Pharma February 14, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.09) | |||
| Market Risk Adjusted Performance | (1.36) | |||
| Mean Deviation | 2.65 | |||
| Coefficient Of Variation | (852.63) | |||
| Standard Deviation | 3.46 | |||
| Variance | 11.96 | |||
| Information Ratio | (0.14) | |||
| Jensen Alpha | (0.43) | |||
| Total Risk Alpha | (0.67) | |||
| Treynor Ratio | (1.37) | |||
| Maximum Drawdown | 16.72 | |||
| Value At Risk | (6.36) | |||
| Potential Upside | 5.25 | |||
| Skewness | (0.16) | |||
| Kurtosis | 0.6993 |
Ascentage Pharma Backtested Returns
Ascentage Pharma secures Sharpe Ratio (or Efficiency) of -0.13, which signifies that the company had a -0.13 % return per unit of standard deviation over the last 3 months. Ascentage Pharma Group exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Ascentage Pharma's mean deviation of 2.65, and Risk Adjusted Performance of (0.09) to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 0.3, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Ascentage Pharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding Ascentage Pharma is expected to be smaller as well. At this point, Ascentage Pharma has a negative expected return of -0.46%. Please make sure to confirm Ascentage Pharma's value at risk, rate of daily change, and the relationship between the total risk alpha and kurtosis , to decide if Ascentage Pharma performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.82 |
Very good predictability
Ascentage Pharma Group has very good predictability. Overlapping area represents the amount of predictability between Ascentage Pharma time series from 16th of November 2025 to 31st of December 2025 and 31st of December 2025 to 14th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Ascentage Pharma price movement. The serial correlation of 0.82 indicates that around 82.0% of current Ascentage Pharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.82 | |
| Spearman Rank Test | 0.78 | |
| Residual Average | 0.0 | |
| Price Variance | 2.79 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Ascentage Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Ascentage Pharma Group reported net income of (395.25 Million). This is 215.81% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 169.22% higher than that of the company.
Ascentage Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ascentage Pharma's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Ascentage Pharma could also be used in its relative valuation, which is a method of valuing Ascentage Pharma by comparing valuation metrics of similar companies.Ascentage Pharma is currently under evaluation in net income category among its peers.
Ascentage Pharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of Ascentage Pharma from analyzing Ascentage Pharma's financial statements. These drivers represent accounts that assess Ascentage Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Ascentage Pharma's important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 7.0B | 7.9B | 8.7B | 38.3B | 34.5B | 36.2B | |
| Enterprise Value | 6.4B | 8.2B | 9.4B | 38.7B | 34.9B | 36.6B |
Ascentage Fundamentals
| Return On Equity | -1.6 | ||||
| Return On Asset | -0.23 | ||||
| Profit Margin | (2.97) % | ||||
| Operating Margin | (2.37) % | ||||
| Current Valuation | 2.21 B | ||||
| Shares Outstanding | 92.96 M | ||||
| Shares Owned By Institutions | 0.07 % | ||||
| Number Of Shares Shorted | 725 | ||||
| Price To Book | 22.38 X | ||||
| Price To Sales | 5.56 X | ||||
| Revenue | 980.65 M | ||||
| Gross Profit | 354.93 M | ||||
| EBITDA | (237.63 M) | ||||
| Net Income | (395.25 M) | ||||
| Total Debt | 1.67 B | ||||
| Book Value Per Share | 0.28 X | ||||
| Cash Flow From Operations | (111.36 M) | ||||
| Short Ratio | 0.20 X | ||||
| Earnings Per Share | (2.10) X | ||||
| Target Price | 45.71 | ||||
| Number Of Employees | 605 | ||||
| Beta | 0.88 | ||||
| Market Capitalization | 2.17 B | ||||
| Total Asset | 2.62 B | ||||
| Retained Earnings | (5.77 B) | ||||
| Working Capital | 307.55 M | ||||
| Net Asset | 2.62 B |
About Ascentage Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ascentage Pharma Group's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ascentage Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ascentage Pharma Group based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Can Biotechnology industry sustain growth momentum? Does Ascentage have expansion opportunities? Factors like these will boost the valuation of Ascentage Pharma. If investors know Ascentage will grow in the future, the company's valuation will be higher. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Ascentage Pharma demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Earnings Share (2.10) | Revenue Per Share | Quarterly Revenue Growth (0.72) | Return On Assets | Return On Equity |
The market value of Ascentage Pharma is measured differently than its book value, which is the value of Ascentage that is recorded on the company's balance sheet. Investors also form their own opinion of Ascentage Pharma's value that differs from its market value or its book value, called intrinsic value, which is Ascentage Pharma's true underlying value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Because Ascentage Pharma's market value can be influenced by many factors that don't directly affect Ascentage Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Ascentage Pharma's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Ascentage Pharma represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Ascentage Pharma's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.